Trial reportJournal of the American Heart Association2022
Short-Term Changes in Left and Right Ventricular Cardiac Magnetic Resonance Feature Tracking Strain Following Ferric Carboxymaltose in Patients With Heart Failure: A Substudy of the Myocardial-IRON Trial.
Trial report in Journal of the American Heart Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03398681 (Changes in Myocardial Iron Content Following Administration of Intravenous Iron), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Changes in Myocardial Iron Content Following Administration of Intravenous Iron (Myocardial-IRON)
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- Changes in platelet count as a marker of myocardial iron uptake after administration of ferric carboxymaltose in patients with heart failure.Scientific reports · 2026Trial
- Improvement in left atrial strain following ferric carboxymaltose in heart failure: an analysis of the Myocardial-IRON trial.ESC heart failure · 2024Trial
- Intravenous ferric carboxymaltose and exercise capacity in iron-deficient kidney transplant recipients: a randomised, placebo-controlled trial in the Netherlands.EClinicalMedicine · 2026Article
- Role of dyssynchrony in short-term left ventricular systolic function after iron repletion in patients with heart failure.Communications medicine · 2026Article
- Baseline serum ferritin predicts myocardial iron uptake following intravenous iron therapy - a hypothesis-generating study.European journal of heart failure · 2025Article
- Myocardial Performance Improvement After Iron Replacement in Heart Failure Patients: The IRON-PATH II Echo-Substudy.Journal of clinical medicine · 2025Article
- Ferric carboxymaltose for iron deficiency in patients with heart failure: a systematic review and meta-analysis.Future science OA · 2024Review
- Identification of three mechanistic pathways for iron-deficient heart failure.European heart journal · 2024Review
- The Impact of Iron Deficiency on Disease Severity and Myocardial Function in Cardiac Amyloidosis.American journal of medicine open · 2024Article
- Iron Status and Cause-Specific Mortality After Kidney Transplantation.Kidney medicine · 2024Article
- Iron Deficiency in Patients with Left Ventricular Assist Devices.Cardiac failure review · 2024Review
- Article
- High salt intake damages myocardial viability and induces cardiac remodelingFrontiers in cardiovascular medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The mechanisms explaining the clinical benefits of ferric carboximaltose (FCM) in patients with heart failure, reduced or intermediate left ventricular ejection fraction, and iron deficiency remain not fully clarified. The Myocardial-IRON trial showed short-term cardiac magnetic resonance (CMR) changes suggesting myocardial iron repletion following administration of FCM but failed to find a significant increase in left ventricular ejection fraction in the whole sample. Conversely, the strain assessment could evaluate more specifically subtle changes in contractility. In this subanalysis, we aimed to evaluate the effect of FCM on the short-term left and right ventricular CMR feature tracking derived strain. Methods and Results This is a post hoc subanalysis of the double-blind, placebo-controlled, randomized clinical trial that enrolled 53 ambulatory patients with heart failure and left ventricular ejection fraction <50%, and iron deficiency [Myocardial-IRON trial (NCT03398681)]. Three-dimensional left and 2-dimensional right ventricular CMR tracking strain (longitudinal, circumferential, and radial) changes were evaluated before, 7 and 30 days after randomization using linear mixed-effect analysis. The median (interquartile range) age of the sample was 73 years (65-78), and 40 (75.5%) were men. At baseline, there were no significant differences in CMR feature tracking strain parameters across both treatment arms. At 7 days, the only global 3-dimensional left ventricular circumferential strain was significantly higher in the FCM treatment-arm (difference: -1.6%,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.